Question · asked by 0 reviews
Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferoxamine: All‐cause mortality
- Population
- improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia
- Intervention
- Summary of findings: Comparison 3 ‐ deferiprone (DFP)
- Comparison
- deferoxamine
- Outcome
- All‐cause mortality
It is very uncertain whether DFP changes all‐cause mortality compared with DFO (very low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
DFP vs DFO All‐cause mortality · improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia It is very uncertain whether DFP changes all‐cause mortality compared with DFO (very low certainty). Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or… (2018) · Cochrane Headline outcomes onlyearlier version CD012349.PUB2, superseded | RR 0.44 [0.12, 1.63] | 1 study · 88 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.